At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 336 target
Drug / intervention
nab-Paclitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating nab-Paclitaxel, Gemcitabine, and 1 other intervention for Breast Cancer. Completed, enrolled 336 participants across 1 site.
Detailed Summary
The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesGermany
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartJun 2013
Primary CompletionMar 2015
Study CompletionJan 2025
TodayJul 2026
First PostedMar 21, 2013
Enrollment StartJun 1, 2013
Primary CompletionMar 1, 2015
Study CompletionJan 15, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.3 years ago
Interventions
nab-Paclitaxeldrug
Gemcitabinedrug
Carboplatindrug